Literature DB >> 26715773

Clinical Outcomes and Prognostic Factors in a Cohort of Adults With Cystic Fibrosis: A 7-Year Follow-Up Study.

Josani Silva Flores1, Paula Maria Eidt Rovedder2, Bruna Ziegler3, Antônio Fernando Furlan Pinotti4, Sérgio Saldanha Menna Barreto5, Paulo de Tarso Roth Dalcin6.   

Abstract

BACKGROUND: Due to the heterogeneity of cystic fibrosis (CF), the longer survival observed in cohorts of adult subjects, and inter-population variations, there is a clear need to seek further information about clinical outcomes and prognostic factors in different cohorts of subjects with CF. Our objectives were to evaluate clinical outcomes and prognostic factors in a cohort of adult subjects with CF after a 7-y follow-up period and investigate longitudinal changes in clinical scores, spirometry, 6-min walk test performance, and pulmonary artery systolic pressure as assessed by Doppler echocardiography.
METHODS: A cohort of clinically stable subjects (≥16 y old) who were enrolled in an adult CF program in 2004-2005 underwent clinical evaluation. Outcome was classified as good (survival) or poor (survival with lung transplantation or death). In 2011-2012, survivors were re-examined.
RESULTS: Of 40 subjects with CF evaluated in 2004-2005, 32 (80%) survived, 2 (5%) survived with lung transplantation, and 6 (15%) died. Logistic regression analysis showed that a low percent-of-predicted FEV1 was associated with poor outcome. An FEV1 cut-off value of ≤30% and pulmonary artery systolic pressure of ≥42 mm Hg predicted poor outcome with high sensitivity, specificity, and positive and negative predictive values. Deterioration was observed in clinical scores (P = .03), FVC (P = .02), FEV1 (P < .001), distance walked in the 6-min walk test (P = .002), baseline SpO2 (P < .001), and final SpO2 (P < .001).
CONCLUSIONS: After 7 y of follow-up, 20% of subjects with CF had a poor outcome. Pulmonary artery systolic pressure of ≥42 mm Hg and FEV1 of ≤30% were the most significant prognostic predictors of poor outcome. Clinical and functional deterioration was observed in survivors.
Copyright © 2016 by Daedalus Enterprises.

Entities:  

Keywords:  cohort studies; cystic fibrosis; lung function; prognosis; pulmonary hypertension

Mesh:

Year:  2015        PMID: 26715773     DOI: 10.4187/respcare.04097

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  3 in total

Review 1.  Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Authors:  Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz
Journal:  J Cyst Fibros       Date:  2019-03-27       Impact factor: 5.482

2.  Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.

Authors:  Jaime L Rubin; Lasair O'Callaghan; Christopher Pelligra; Michael W Konstan; Alexandra Ward; Jack K Ishak; Conor Chandler; Theodore G Liou
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

3.  Predictors of deterioration of lung function in Polish children with cystic fibrosis.

Authors:  Małgorzata Olszowiec-Chlebna; Agnieszka Koniarek-Maniecka; Włodzimierz Stelmach; Katarzyna Smejda; Joanna Jerzyńska; Paweł Majak; Monika Białas; Iwona Stelmach
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.